Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaoping LiBNBo NiePZPeng Zhao

Discussion

Loading...

Member takes

Overview

Prospective study shows high engraftment and low complication rates in haploidentical HSCT for SAA, suggesting FCM may improve outcomes.

Key Points

  • All patients achieved successful engraftment with median neutrophil and platelet times of 13 and 12 days respectively, indicating the regimen's effectiveness.
  • The acute graft-versus-host disease rates were 20% for grade II-IV, demonstrating manageable safety outcomes with FCM.
  • Transplantation-related mortality rate was low at 4%, underscoring the regimen's favorable profile compared to traditional methods.
  • The protocol included multiple supportive measures, such as antifungal treatment, to reduce post-transplant complications.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d89fhttps://doi.org/10.1182/blood-2025-4201
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia2025
  2. 2The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.2025
  3. 3Outcomes of hematopoietic stem cell transplantation using melphalan-based conditioning in children with acquired aplastic anemia2025
  4. 4A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity2025
  5. 5An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025